Here, we expand the repertoire of PROTAC compatible E3 ligases by identifying a novel small molecule scaffold targeting the ubiquitin E3 ligase KLHDC2 using a fluorescence polarization-based high ...

Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural protein disposal systems ...

Aurigene Oncology Ltd. has patented new proteolysis targeting chimera (PROTACs) compounds comprising a protein cereblon (CRBN)-binding moiety covalently bound to a CREB-binding protein (CREBBP; ...

Jiangsu Simcere Pharmaceutical Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase binding moiety coupled to an interleukin-1 ...

Researchers from the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences constructed a ...

Daohong Zhou and Aileen Frost explore how they target the proteolysis mechanism and fight cancer using proteolysis targeting chimera (PROTAC) technology. A series of rodent experiments showed that ...

ARV-393 is an investigational PROteolysis TArgeting Chimera (PROTAC) designed to degrade the BCL6 protein, a key driver of B-cell lymphomas. ARV-393 shows strong synergistic antitumor activity ...

The data suggest that ARV-393, a PROteolysis TArgeting Chimera (PROTAC) designed to degrade the B-cell lymphoma 6 protein (BCL6), may effectively combine with existing lymphoma treatments to ...

Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of ...

ARV-393 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas.

Arvinas, Inc. (NASDAQ:ARVN) develops treatments that break down disease-causing proteins using its PROTAC (Proteolysis Targeting Chimera) technology. The company’s main drugs target prostate ...